Cancer
Malignant Kidney Neoplasm
CI-CAN-00003171Explore in graph →
Top-level453 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003171Explore in graph →
Clinical trials
2,143 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (339)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06778538 | Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients(HPGD-ccRCC) | completed | — | 40 | Shang PanfengOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06775574 | Prognostic Significance of the Lung Immune Prognostic Index (LIPI) in Postoperative Clear Cell Renal Cell Carcinoma: a Multicenter Retrospective Cohort Study | completed | — | 704 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| 1 |
| Jan 15, 2025 |
| clinicaltrials |
| NCT01884961 | Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2(IL2HD) | completed | Phase 2 | 46 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT02761057 | Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed | completed | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 2 | Jan 13, 2025 | clinicaltrials |
| NCT04068831 | Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05461027 | Percutaneous Cryoablation of Central Kidney Tumours With Temporary Renal Artery Occlusion(CP-Renal) | completed | — | 16 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03138512 | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney(CheckMate 914) | completed | Phase 3 | 1,641 | Bristol-Myers SquibbINDUSTRY | 25 | Dec 18, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04957160 | Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination(CARINA) | completed | — | 281 | IpsenINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02926053 | TIL Therapy for Metastatic Renal Cell Carcinoma | completed | Phase 1 | 5 | Inge Marie SvaneOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT03015740 | Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02619253 | Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma | completed | Phase 1 | 52 | Nabil AdraOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT02639182 | A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma | completed | Phase 2 | 133 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Nov 18, 2024 | clinicaltrials |
| NCT04504669 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | completed | Phase 1 | 60 | AstraZenecaINDUSTRY | 4 | Nov 5, 2024 | clinicaltrials |
| NCT02819596 | MEDI4736 Combinations in Metastatic Renal Cell Carcinoma(CALYPSO) | completed | Phase 2 | 69 | Queen Mary University of LondonOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT01672775 | A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology | completed | Phase 1 | 34 | Agensys, Inc.INDUSTRY | 2 | Nov 1, 2024 | clinicaltrials |
| NCT06656039 | A Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma | completed | — | 1,200 | RenJi HospitalOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT04883827 | Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer | completed | — | 180 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06648902 | Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue | completed | Phase 1 / Phase 2 | 60 | Kidney Cancer Research BureauOTHER | 3 | Oct 18, 2024 | clinicaltrials |
| NCT04005183 | Renal Cell Carcinoma Microenvironment Discovery Project(REMEDY) | completed | — | 146 | University Health Network, TorontoOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03109015 | Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing(ASSET) | completed | Phase 2 | 7 | Duke UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06607809 | Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCC(IMNR) | completed | — | 99 | Dr. Lutfi Kirdar Kartal Training and Research HospitalOTHER_GOV | 1 | Oct 8, 2024 | clinicaltrials |
| NCT02667886 | Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 74 | X4 PharmaceuticalsINDUSTRY | 2 | Oct 3, 2024 | clinicaltrials |
| NCT05363072 | A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland. | completed | — | 1,112 | PfizerINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT01210482 | Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) | completed | — | 1,050 | PfizerINDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
| NCT03108066 | MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) | completed | Phase 2 | 4 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Sep 24, 2024 | clinicaltrials |
| NCT01263769 | Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC) | completed | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04375150 | Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC | completed | — | 355 | PfizerINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05485896 | Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC | completed | Phase 2 | 23 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03334344 | Using Virtual Reality (VR) Models for Preoperative Planning | completed | N/A | 92 | Ceevra, Inc.INDUSTRY | 1 | Aug 29, 2024 | clinicaltrials |
| NCT00554515 | The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma(SELECT) | completed | Phase 2 | 123 | Beth Israel Deaconess Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05112627 | Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy | completed | — | 15 | Mayo ClinicOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03133286 | Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)(RADIANT) | completed | — | 16 | DxTerity DiagnosticsINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06543095 | Rib Removal and Pain in Partial Nephrectomy | completed | — | 50 | TC Erciyes UniversityOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06531629 | Risk-based Screen and Prognostic Analysis for Second Primary Malignancies in Kidney Cancer Patients | completed | — | 72,408 | Peking University First HospitalOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06525467 | Primary Renal Lymphoma on a 48 Year Old Woman | completed | — | 1 | Instituto Mexicano del Seguro SocialOTHER_GOV | 1 | Jul 29, 2024 | clinicaltrials |
| NCT03513952 | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03200587 | Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC) | completed | Phase 1 | 12 | University of UtahOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03502330 | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | completed | Phase 1 | 42 | Yale UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03829111 | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | completed | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT00026663 | Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance | completed | — | 86 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2024 | clinicaltrials |
| NCT01326871 | A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer | completed | Phase 1 / Phase 2 | 68 | Altor BioScienceINDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 16, 2025source: clinicaltrials